Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691478 | 1.00 | NR1I2 (0.41) | NR1I2ALBPDE4DIRAK4ABCB1 | |
| SCHEMBL13790123 | 1.00 | NR1I2 (0.41) | NR1I2ALBPDE4DIRAK4ABCB1 | |
| SCHEMBL6691481 | 1.00 | NR1I2 (0.41) | NR1I2ALBPDE4DIRAK4ABCB1 | |
| SCHEMBL18480735 | 0.87 | NR1I2 (0.33) | NR1I2ALBPDE4D | |
| SCHEMBL13789991 | 0.87 | NR1I2 (0.39) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL20616297 | 0.85 | NR1I2 (0.32) | NR1I2ALBPDE4D | |
| SCHEMBL5117081 | 0.83 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL14049050 | 0.83 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL4980179 | 0.83 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL331086 | 0.83 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | UNIV LIVERPOOL (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | UNIV LIVERPOOL (GB) | 2019-01-03 | — | — | US | disclosed |
| WO-2017021716-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097723-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| EP-2125814-B1 | PROCESS FOR THE PREPARATION OF ABACAVIR | ESTEVE QUIMICA SA (ES) | 2010-07-14 | — | — | EP | disclosed |
| US-20100041883-A1 | Process for the preparation of abacavir | Esteve Química, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| US-20100041883-A1 | Process for the preparation of abacavir | Esteve Química, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| US-20100041883-A1 | Process for the preparation of abacavir | Esteve Química, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| EP-0921121-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| US-5840990-A | ENANTIOMORPHS AND VIRICIDES FOR CHEMICAL INTERMEDIATES | GLAXO WELLCOME INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5641889-A | AMINO-HYDROXY-CYCLOPENTENE INTERMEDIATES FOR PURINE NUCLEOSIDES; VIRICIDES | GLAXO WELLCOME INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0349242-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-03-22 | — | — | EP | disclosed |
| EP-0628044-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993017020-A2 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | disclosed |
| EP-0325460-B1 | DIDEOXYDIDEHYDROCARBOCYCLIC NUCLEOSIDES | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1992-10-21 | — | — | EP | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| EP-0349242-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| EP-0325460-A1 | Dideoxydidehydrocarbocyclic nucleosides | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | MAVS, TYMP, SAMHD1 | NR1I2 2110/4885ALB 4515/4885PDE4D 460/4885 |
| US-20100041883-A1 | Process for the preparation of abacavir | CYP4A11, CYP4F11, CYP3A4 | NR1I2 3021/4885ALB 3231/4885PDE4D 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.